JP2017508455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017508455A5 JP2017508455A5 JP2016553591A JP2016553591A JP2017508455A5 JP 2017508455 A5 JP2017508455 A5 JP 2017508455A5 JP 2016553591 A JP2016553591 A JP 2016553591A JP 2016553591 A JP2016553591 A JP 2016553591A JP 2017508455 A5 JP2017508455 A5 JP 2017508455A5
- Authority
- JP
- Japan
- Prior art keywords
- glucuronidase
- recombinant human
- mol
- composition
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 15
- 230000009450 sialylation Effects 0.000 claims 3
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461948421P | 2014-03-05 | 2014-03-05 | |
| US61/948,421 | 2014-03-05 | ||
| US201562114313P | 2015-02-10 | 2015-02-10 | |
| US62/114,313 | 2015-02-10 | ||
| PCT/US2015/018859 WO2015134696A1 (en) | 2014-03-05 | 2015-03-05 | Sialylated glycoprotein compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017508455A JP2017508455A (ja) | 2017-03-30 |
| JP2017508455A5 true JP2017508455A5 (enExample) | 2018-03-01 |
| JP6581590B2 JP6581590B2 (ja) | 2019-09-25 |
Family
ID=54016314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553591A Active JP6581590B2 (ja) | 2014-03-05 | 2015-03-05 | シアル化糖タンパク質組成物及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (8) | US9457067B2 (enExample) |
| EP (1) | EP3113781B1 (enExample) |
| JP (1) | JP6581590B2 (enExample) |
| KR (1) | KR102150481B1 (enExample) |
| CN (1) | CN106102749B (enExample) |
| AU (1) | AU2015227137B2 (enExample) |
| BR (1) | BR112016019893B1 (enExample) |
| CA (1) | CA2940318C (enExample) |
| ES (1) | ES2704923T3 (enExample) |
| IL (1) | IL247550B (enExample) |
| MX (1) | MX368972B (enExample) |
| MY (1) | MY188028A (enExample) |
| PE (1) | PE20161417A1 (enExample) |
| PH (1) | PH12016501658A1 (enExample) |
| RU (1) | RU2689119C2 (enExample) |
| TW (1) | TWI702049B (enExample) |
| WO (1) | WO2015134696A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102150481B1 (ko) | 2014-03-05 | 2020-09-02 | 울트라제닉스 파마수티컬 인코포레이티드 | 시알화 당단백질 조성물 및 이의 용도 |
| EP3724314A1 (en) | 2017-12-13 | 2020-10-21 | 3M Innovative Properties Company | Water-reconstitutable culture medium resistant to liquefaction by microorganisms |
| TWI667252B (zh) * | 2018-07-13 | 2019-08-01 | 中原大學 | 阿伐-選擇性唾液酸供體及其於製備唾液酸苷的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458574B1 (en) * | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| SI1543106T1 (sl) * | 2002-07-15 | 2007-08-31 | Immunex Corp | Postopki in mediji za nadziranje sialilacije proteinov, ki jih proizvajajo sesalske celice |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| PT1699821E (pt) * | 2003-12-31 | 2012-08-23 | Merck Patent Gmbh | Proteína de fusão fc-eritropoietina com farmacocinética melhorada |
| EP1818395A1 (en) * | 2006-02-08 | 2007-08-15 | Diatos | Compositions and methods for treating lysosomal storage diseases |
| ES2533964T5 (es) * | 2006-09-10 | 2024-05-09 | Glycotope Gmbh | Uso de células humanas de origen leucémico mieloide para expresión de anticuerpos |
| US20090041741A1 (en) * | 2007-03-06 | 2009-02-12 | Saint Louis University | Modified enzyme and treatment method |
| KR101241322B1 (ko) * | 2010-02-08 | 2013-03-11 | 한국과학기술원 | 시알산 함량이 높은 재조합 당단백질의 제조 방법 |
| WO2012101671A1 (en) * | 2011-01-25 | 2012-08-02 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human recombinant iduronate 2-sulfatase |
| KR101457514B1 (ko) * | 2011-11-21 | 2014-11-03 | 한국생명공학연구원 | 우렁쉥이(멍게) 유래의 시알산 전이효소 및 이를 이용한 시알화 복합당질 합성 방법 |
| US10138474B2 (en) * | 2012-08-17 | 2018-11-27 | Research Foundation Of The City University Of New York | Scavenger receptor uptake for fabry disease enzyme replacement therapy |
| KR102150481B1 (ko) | 2014-03-05 | 2020-09-02 | 울트라제닉스 파마수티컬 인코포레이티드 | 시알화 당단백질 조성물 및 이의 용도 |
-
2015
- 2015-03-05 KR KR1020167026994A patent/KR102150481B1/ko active Active
- 2015-03-05 US US14/639,171 patent/US9457067B2/en active Active
- 2015-03-05 WO PCT/US2015/018859 patent/WO2015134696A1/en not_active Ceased
- 2015-03-05 JP JP2016553591A patent/JP6581590B2/ja active Active
- 2015-03-05 PE PE2016001535A patent/PE20161417A1/es not_active Application Discontinuation
- 2015-03-05 MY MYPI2016001608A patent/MY188028A/en unknown
- 2015-03-05 BR BR112016019893-0A patent/BR112016019893B1/pt active IP Right Grant
- 2015-03-05 ES ES15758766T patent/ES2704923T3/es active Active
- 2015-03-05 RU RU2016138790A patent/RU2689119C2/ru active
- 2015-03-05 TW TW104107083A patent/TWI702049B/zh active
- 2015-03-05 AU AU2015227137A patent/AU2015227137B2/en active Active
- 2015-03-05 CA CA2940318A patent/CA2940318C/en active Active
- 2015-03-05 MX MX2016011416A patent/MX368972B/es active IP Right Grant
- 2015-03-05 EP EP15758766.8A patent/EP3113781B1/en active Active
- 2015-03-05 CN CN201580015886.XA patent/CN106102749B/zh active Active
- 2015-09-10 US US14/849,745 patent/US9457068B2/en active Active
-
2016
- 2016-08-19 PH PH12016501658A patent/PH12016501658A1/en unknown
- 2016-08-30 US US15/251,701 patent/US9687532B2/en active Active
- 2016-08-30 IL IL247550A patent/IL247550B/en active IP Right Grant
-
2017
- 2017-05-26 US US15/607,257 patent/US9937243B2/en active Active
-
2018
- 2018-04-02 US US15/943,526 patent/US20190054153A1/en not_active Abandoned
-
2020
- 2020-01-09 US US16/738,938 patent/US20200282028A1/en not_active Abandoned
-
2021
- 2021-11-11 US US17/524,628 patent/US20220202915A1/en not_active Abandoned
-
2023
- 2023-12-07 US US18/532,665 patent/US20240245759A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02662B (me) | Niskofrekventna terapija glatiramer acetatom | |
| JP2016516016A5 (enExample) | ||
| WO2009033711A3 (en) | Use of glp-1 as a therapeutic agent | |
| JP2011225596A5 (enExample) | ||
| WO2009033762A3 (en) | Use of endothelin-3 as a therapeutic agent | |
| FI2981255T3 (fi) | Empagliflotsiinin terapeuttiset käytöt | |
| WO2009033770A3 (en) | Calcitonin c-terminal flanking peptide for use as a therapeutic agent | |
| HRP20240034T1 (hr) | Liječenje kardiovaskularnih bolesti | |
| JP2015519329A5 (enExample) | ||
| JP2011528333A5 (enExample) | ||
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| JP2021509916A5 (enExample) | ||
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| JP2020500864A5 (enExample) | ||
| JP2017508455A5 (enExample) | ||
| JP2007119497A5 (enExample) | ||
| JP2015504094A5 (enExample) | ||
| WO2016122806A8 (en) | Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life | |
| JP2017061488A5 (enExample) | ||
| JP2015518002A5 (enExample) | ||
| Samad et al. | Intracerebral coinfection with Burkholderia pseudomallei and Cryptococcus neoformans in a patient with systemic lupus erythematosus | |
| RU2016138790A (ru) | Композиции на основе сиалированных гликопротеинов и их применение | |
| JP2015524808A5 (enExample) | ||
| NZ708511A (en) | Methods for controlling blood pressure and reducing dyspnea in heart failure |